Author(s):
Sabitha. S, Soniya Gandhi. A
Email(s):
annasoniya995@gmail.com
DOI:
10.52711/jnmr.2026.22 
Address:
Sabitha. S1, Soniya Gandhi. A2*
1Professor, RVS College of Nursing, Coimbatore – 641402, Tamilnadu, India.
2Assistant Professor, RVS College of Nursing, Coimbatore – 641402, Tamilnadu, India.
*Corresponding Author
Published In:
Volume - 5,
Issue - 3,
Year - 2026
ABSTRACT:
Neurocysticercosis (NCC) is a parasitic infection of the central nervous system caused by the larval form of Taenia solium and is a leading cause of acquired epilepsy worldwide. Although antiparasitic therapy is generally effective, recurrence after a prolonged asymptomatic period is rare and poorly documented. This case study reports a rare recurrence of neurocysticercosis in a 38-year-old female who presented with recurrent seizures, headache, vomiting, and visual disturbances 18 years after initial treatment. Magnetic resonance imaging revealed multiple ring-enhancing lesions with perilesional edema suggestive of active parenchymal neurocysticercosis, while computed tomography showed calcified granulomas indicating previous healed lesions. Serological tests were positive for T. solium antibodies, and mild eosinophilia was observed. The patient was treated with albendazole, corticosteroids, and antiepileptic drugs, resulting in significant clinical improvement. Nursing management included seizure monitoring, medication administration, patient education, and preventive counseling on hygiene and sanitation. This case highlights the importance of long-term follow-up, early diagnosis, interdisciplinary management, and nursing interventions in preventing complications and recurrence of neurocysticercosis in endemic regions.
Cite this article:
Sabitha. S, Soniya Gandhi. A. Case study on Reactivation or Reinfection? A Rare case of Neurocysticercosis Recurring after 18 years. A and V Pub Journal of Nursing and Medical Research. 2026;5(3):105-8. doi: 10.52711/jnmr.2026.22
Cite(Electronic):
Sabitha. S, Soniya Gandhi. A. Case study on Reactivation or Reinfection? A Rare case of Neurocysticercosis Recurring after 18 years. A and V Pub Journal of Nursing and Medical Research. 2026;5(3):105-8. doi: 10.52711/jnmr.2026.22 Available on: https://jnmronline.com/AbstractView.aspx?PID=2026-5-3-1
REFERENCE:
1. García HH, Nash TE, Del Brutto OH. Clinical symptoms, diagnosis, and treatment of neurocysticercosis. Lancet Neurol. 2014; 13(12): 1202–15.
2. White AC, Coyle CM, Rajshekhar V, Singh G, Hauser WA, Mohanty A, et al. Neurocysticercosis: Updates in diagnosis and management. Annu Rev Med. 2018; 69: 117–28.
3. World Health Organization. Taeniasis/cysticercosis fact sheet. Geneva: World Health Organization; 2023.
4. Del Brutto OH. Diagnostic criteria for neurocysticercosis revisited. Pathog Glob Health. 2012; 106(5): 299–304.
5. Wallin MT, Kurtzke JF. Neurocysticercosis in the United States: Review of an important emerging infection. Neurology. 2004; 63(9): 1559–64.
6. Carpio A. Neurocysticercosis: Clinical spectrum and treatment. Neurol Clin. 2018; 36(4): 799–814.
7. Proaño JV, Madrazo I, Avelar F, López-Félix B, Díaz G, Grijalva I. Immunopathology of neurocysticercosis. Parasite Immunol. 2002; 24(4): 159–65.
8. Rajshekhar V. Diagnosis and management of solitary cysticercus granuloma of the brain. Neurol India. 2016; 64(6): 1020–5.
9. Hauser WA. Seizure disorders in parasitic infections of the central nervous system. Epilepsia. 2003; 44(Suppl 1): 48–53.
10. Garcia HH, Gonzalez AE, Evans CA, Gilman RH. Taenia solium cysticercosis. Lancet. 2003; 362(9383): 547–56.
11. Singh G, Rajshekhar V, Murthy JM, Prabhakar S, Modi M, Khandelwal N, et al. A diagnostic and therapeutic scheme for solitary cysticercus granuloma. Neurology. 2010;75(24):2236–45.
12. Nash TE, Garcia HH. Diagnosis and treatment of neurocysticercosis. Nat Rev Neurol. 2011; 7(10): 584–94.
13. Del Brutto OH, Garcia HH. Neurocysticercosis: A frequent cause of epilepsy worldwide. Lancet Neurol. 2012; 11(12): 1021–30.
14. Fleury A, Dessein A, Preux PM, Dumas M, Tapia G, Larralde C, et al. Symptomatic human neurocysticercosis: A systematic review. Lancet Infect Dis. 2006; 6(10): 653–62.
15. Garcia HH, Pretell EJ, Gilman RH, Martinez SM, Moulton LH, Del Brutto OH, et al. A trial of antiparasitic treatment to reduce seizures due to cerebral cysticercosis. N Engl J Med. 2004; 350(3): 249–58.
16. Singh G, Burneo JG, Sander JW. From seizures to epilepsy and its substrates: Neurocysticercosis. Epilepsia. 2013; 54(5): 783–92.
17. Garcia HH, O'Neal SE, Noh J, Handali S; Cysticercosis Working Group in Peru. Neurocysticercosis: Pathogenesis, diagnosis, and treatment. Clin Microbiol Rev. 2020; 33(1): e00016-19.
18. Del Brutto OH, Arroyo G, Del Brutto VJ. Neurocysticercosis: Epidemiology and clinical features. Clin Neurol Neurosurg. 2019; 186: 105515.
19. World Health Organization. Preventing neurocysticercosis: A public health strategy. WHO Technical Report Series. Geneva: WHO; 2015.
20. Carabin H, Traoré AA. Taenia solium cysticercosis and epilepsy in Africa: Review. Trans R Soc Trop Med Hyg. 2014; 108(10): 601–12.